IL315174A - Abiraterone decanoate drug metrics and treatment use - Google Patents

Abiraterone decanoate drug metrics and treatment use

Info

Publication number
IL315174A
IL315174A IL315174A IL31517424A IL315174A IL 315174 A IL315174 A IL 315174A IL 315174 A IL315174 A IL 315174A IL 31517424 A IL31517424 A IL 31517424A IL 315174 A IL315174 A IL 315174A
Authority
IL
Israel
Prior art keywords
abiraterone
decanoate
prodrugs
therapy
decanoate prodrugs
Prior art date
Application number
IL315174A
Other languages
English (en)
Hebrew (he)
Original Assignee
Propella Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Propella Therapeutics Inc filed Critical Propella Therapeutics Inc
Publication of IL315174A publication Critical patent/IL315174A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL315174A 2022-03-01 2023-02-15 Abiraterone decanoate drug metrics and treatment use IL315174A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263315240P 2022-03-01 2022-03-01
US202263425839P 2022-11-16 2022-11-16
PCT/US2023/013116 WO2023167783A1 (en) 2022-03-01 2023-02-15 Abiraterone decanoate prodrugs and use in therapy

Publications (1)

Publication Number Publication Date
IL315174A true IL315174A (en) 2024-10-01

Family

ID=85724851

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315174A IL315174A (en) 2022-03-01 2023-02-15 Abiraterone decanoate drug metrics and treatment use

Country Status (12)

Country Link
US (1) US20250186463A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486353A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508944A (cg-RX-API-DMAC7.html)
KR (1) KR20240167653A (cg-RX-API-DMAC7.html)
CN (1) CN119136813A (cg-RX-API-DMAC7.html)
AU (1) AU2023229152A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243913A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002613A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024013267A2 (cg-RX-API-DMAC7.html)
IL (1) IL315174A (cg-RX-API-DMAC7.html)
MX (1) MX2024010741A (cg-RX-API-DMAC7.html)
WO (1) WO2023167783A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021338271A1 (en) * 2020-09-02 2023-03-30 Astellas Us Llc Abiraterone prodrugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
AU2019362061B2 (en) 2018-10-18 2024-09-26 Essa Pharma Inc Androgen receptor modulators and methods for their use
CN114026106B (zh) * 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
CN117120034A (zh) 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
WO2023038933A1 (en) * 2021-09-08 2023-03-16 Propella Therapeutics, Inc. Oral abiraterone formulations

Also Published As

Publication number Publication date
MX2024010741A (es) 2024-09-10
CA3243913A1 (en) 2023-09-07
CO2024013267A2 (es) 2024-10-10
WO2023167783A1 (en) 2023-09-07
CL2024002613A1 (es) 2025-02-07
US20250186463A1 (en) 2025-06-12
CN119136813A (zh) 2024-12-13
EP4486353A1 (en) 2025-01-08
KR20240167653A (ko) 2024-11-27
AU2023229152A1 (en) 2024-09-05
JP2025508944A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
SG11202108331XA (en) Adjustable expiratory relief in respiratory therapy
GB202014736D0 (en) Novel compounds and their use in therapy
IL277904A (en) History of indan for use in the treatment of pain and inflammation
GB202002339D0 (en) A wound dressing and a wound therapy apparatus
IL312286A (en) Topical compounds and methods for photodynamic therapy
GB202108572D0 (en) Therapeutic compounds and their use
GB201820659D0 (en) Novel compostions and their use in therapy
GB202019475D0 (en) Therapeutic compounds and their use
EP4238600A4 (en) VENTILATION SOUND REDUCTION APPARATUS AND VENTILATION THERAPY DEVICE
IL309249A (en) Conjugates including phosphoantigens and their use in therapy
IL321265A (en) Cancer treatment with captopril and fulvestrant
EP4228710A4 (en) Radiolabeled therapeutic conjugates and their use in therapy
GB202403391D0 (en) Novel compounds and their use in therapy
IL277903A (en) History of indan for use in the treatment of pain and inflammation
EP4645663A4 (en) PARALLEL POWER SUPPLY DEVICE AND PROGRAM
IL277905A (en) The history of hexadecahydro-1H-cyclopenta[A]phenanthrene for the treatment of pain and inflammation
EP4401750C0 (en) COMPOSITION CONTAINS IL-36 AND OPTIONALLY IL-18 FOR USE IN THE TREATMENT OF EYE DISEASES
GB202305546D0 (en) Novel compounds and their use in therapy
GB202305541D0 (en) Novel compounds and their use in therapy
GB202102987D0 (en) Dosimeter apparatus and methods
GB202215142D0 (en) Novel cell lines and their use in therapy
GB202110932D0 (en) Novel compounds and their use in therapy
GB202011808D0 (en) Novel compounds and their use in therapy
PT4284843T (pt) Sialósidos inovadores e sua utilização em terapia
GB202001209D0 (en) Novel compounds and their use in therapy